Bhawna Gupta1, Newell W Johnson, Narinder Kumar. 1. School of Dentistry and Oral Health, Menzies Health Institute Queensland, Griffith University, Gold Coast, Qld., Australia.
Abstract
BACKGROUND: Head and neck cancers (HNCs) continue to remain a significant public health burden worldwide, causing significant mortality and morbidity despite significant clinical advances enabling their early diagnosis and treatment. METHODS: We used data from the GLOBOCAN 2012, Cancer Incidence in Five Continents, World Health Organization Mortality Database and Surveillance, Epidemiology, and End Results programmes to describe the current epidemiology of HNCs. RESULTS: Estimated age-standardised incidence/mortality rates for cancers of the lip and oral cavity among males and females (7.0/2.3 and 2.6/0.6 per 100,000 per annum) in more developed regions are higher compared to those in less developed regions (5.0/2.8 and 2.5/1.4 per 100,000 per annum). Similarly, the estimated rates for cancers of the tonsils and pharynx among males (7.5/2.5 per 100,000 per annum) and females (2.7/0.5 per 100,000 per annum) are reported to be the highest in Western Europe, whereas these rates for cancer of the larynx among males (7.9/4.0 per 100,000 per annum) and females (0.9/0.5 per 100,000 per annum) are reported to be the highest in the Caribbean. Cancer of the nasopharynx represents a significant HNC burden in the Asia-Pacific region and Northern Africa. CONCLUSION: The current and future estimated burden of HNCs is shifting to less developed regions which may be ill equipped to deal with this increasing burden. This needs urgent attention of policy makers through effective cancer control policy implementation with population-based interventions.
BACKGROUND: Head and neck cancers (HNCs) continue to remain a significant public health burden worldwide, causing significant mortality and morbidity despite significant clinical advances enabling their early diagnosis and treatment. METHODS: We used data from the GLOBOCAN 2012, Cancer Incidence in Five Continents, World Health Organization Mortality Database and Surveillance, Epidemiology, and End Results programmes to describe the current epidemiology of HNCs. RESULTS: Estimated age-standardised incidence/mortality rates for cancers of the lip and oral cavity among males and females (7.0/2.3 and 2.6/0.6 per 100,000 per annum) in more developed regions are higher compared to those in less developed regions (5.0/2.8 and 2.5/1.4 per 100,000 per annum). Similarly, the estimated rates for cancers of the tonsils and pharynx among males (7.5/2.5 per 100,000 per annum) and females (2.7/0.5 per 100,000 per annum) are reported to be the highest in Western Europe, whereas these rates for cancer of the larynx among males (7.9/4.0 per 100,000 per annum) and females (0.9/0.5 per 100,000 per annum) are reported to be the highest in the Caribbean. Cancer of the nasopharynx represents a significant HNC burden in the Asia-Pacific region and Northern Africa. CONCLUSION: The current and future estimated burden of HNCs is shifting to less developed regions which may be ill equipped to deal with this increasing burden. This needs urgent attention of policy makers through effective cancer control policy implementation with population-based interventions.
Authors: Cheng Lu; James S Lewis; William D Dupont; W Dale Plummer; Andrew Janowczyk; Anant Madabhushi Journal: Mod Pathol Date: 2017-08-04 Impact factor: 7.842
Authors: Thomas Kuhnt; Andreas Schreiber; Anett Pirnasch; Matthias G Hautmann; Peter Hass; Frank P Sieker; Rita Engenhart-Cabillic; Michael Richter; Kathrin Dellas; Jürgen Dunst Journal: Strahlenther Onkol Date: 2017-05-12 Impact factor: 3.621
Authors: Daniela Russo; Francesco Merolla; Silvia Varricchio; Giovanni Salzano; Giovanni Zarrilli; Massimo Mascolo; Viviana Strazzullo; Rosa Maria Di Crescenzo; Angela Celetti; Gennaro Ilardi Journal: Biomed Rep Date: 2018-07-27
Authors: Chindhu Shunmuga Sundaram; Haryana M Dhillon; Phyllis N Butow; Puma Sundaresan; Claudia Rutherford Journal: Support Care Cancer Date: 2019-06-15 Impact factor: 3.603